Runt-Related Transcription Factor 1, Translocated To, 1 (Cyclin D-Related) (RUNX1T1) Kits ELISA

RUNX1T1 encodes a member of the myeloid translocation gene family which interact with DNA-bound transcription factors and recruit a range of corepressors to facilitate transcriptional repression. De plus, nous expédions RUNX1T1 Anticorps (52) et RUNX1T1 Protéines (6) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
RUNX1T1 862 Q06455
RUNX1T1 12395 Q61909
Anti-Rat RUNX1T1 RUNX1T1 362489  
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top RUNX1T1 Kits ELISA sur anticorps-enligne.fr

Showing 2 out of 4 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Fournisseur Livraison Prix Détails
Souris < 46.9 pg/mL 78 pg/mL - 5000 pg/mL   96 Tests Connectez-vous pour afficher 11 to 18 Days
$810.17
Détails
Humain < 0.188 ng/mL 0.313 ng/mL - 20 ng/mL   96 Tests Connectez-vous pour afficher 11 to 18 Days
$810.17
Détails

Plus Kits ELISA pour RUNX1T1 partenaires d'interaction

Human Runt-Related Transcription Factor 1, Translocated To, 1 (Cyclin D-Related) (RUNX1T1) interaction partners

  1. PKM2 as a novel target of RUNX1-ETO and is specifically downregulated in RUNX1-ETO positive AML patients, indicating that PKM2 level might have a diagnostic potential in RUNX1-ETO associated AML.

  2. The specific association of ZBTB7A mutations with t(8;21) rearranged acute myeloid leukaemia points towards leukemogenic cooperativity between mutant ZBTB7A and the RUNX1/RUNX1T1 fusion protein has been reported.

  3. Data indicate miR-29b-1 as a regulator of the AML1-ETO protein (RUNX1-RUNX1T1), and that miR-29b-1 expression in t(8;21)-carrying leukemic cell lines partially rescues the leukemic phenotype.

  4. Altogether, these results revealed an unexpected and important epigenetic mini-circuit of AML1-ETO/THAP10/miR-383 in t(8;21) acute myeloid leukaemia, in which epigenetic suppression of THAP10 predicts a poor clinical outcome and represents a novel therapeutic target.

  5. RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation. Over 90% of the 175 patients who were in continuous complete remission had a >/=3-log reduction in RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a >/=4-log reduction at >/=12 months.

  6. The data suggest that the tumor suppressor activity of both RUNX1t1 and TFF1 are mechanistically connected to CEBPB and that cross-regulation between CEBPB-RUNX1t1-TFF1 plays an important role in gastric carcinogenesis.

  7. RUNX1T1 serves as a common angiogenic driver for vaculogenesis and functionality of endothelial lineage cells

  8. Leukaemogenesis by AML1-ETO requires enhanced C/D box snoRNA/RNP formation.

  9. Study demonstrated that TRiC's contribution to the activity of the DNA-binding domain (AML1-175) of AML1-ETO is consistent with its contribution to the activity of full-length AML1-ETO and is mediated through its direct association with the DNA-binding domain

  10. the AML1-ETO fusion protein increases the expression of SIRT1, possibly by binding to the promoter region of SIRT1 to activate its transcription in t(8;21) AML.

  11. A feedback circuitry involving miR-9-1 and RUNX1-RUNX1T1.

  12. The role of RUNX1T1 in t(8;21) acute myeloid leukemia and miRNA expression regulation

  13. Our data revealed a novel role for RUNX1T1 as a tumor-suppressor gene in colorectal cancer through modulation of multiple cellular pathways affecting the cell cycle, DNA damage, DNA replication, estrogen signaling, and drug resistance

  14. Exon splicing patterns in the human RUNX1-RUNX1T1 fusion gene present in acute myeloid leukemia patients have been decoded.

  15. Data suggest that biosynthesis and folding of leukemogenic fusion oncoprotein AML1-ETO/RUNX1-RUNX1T1 is facilitated by interaction with the chaperonin TRiC/CCT1/TCP1 and HSP70 (heat shock protein 70).

  16. AML1/ETO transactivates gene expression through recruiting AP-1 to the AML1/ETO-AML1 complex.

  17. A substantial fraction of AML1-ETO/p300 co-localization occurs near TSSs in promoter regions associated with transcriptionally active loci.

  18. minimal residual disease determined by RUNX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation t(8;21) (q22;q22) acute myeloid leukemia patients who are at high risk for relapse, together with c-KIT mutations

  19. identify a high-frequency mutation in t(8;21)/RUNX1-RUNX1T1 acute myekoid leukemia (AML) and identify the need for future studies to investigate the clinical and biological relevance of ASXL2 mutations in this unique subset of AML

  20. RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors are rescued by activating c-Kit mutations

Mouse (Murine) Runt-Related Transcription Factor 1, Translocated To, 1 (Cyclin D-Related) (RUNX1T1) interaction partners

  1. Results suggest that AML1/ETO expression determines a more mobile and less adherent phenotype in preleukemic cells, therefore altering the interaction with the hematopoietic niche, potentially leading to the migration across the bone marrow barrier and to disease progression

  2. The data suggest that the tumor suppressor activity of both RUNX1t1 and TFF1 are mechanistically connected to CEBPB and that cross-regulation between CEBPB-RUNX1t1-TFF1 plays an important role in gastric carcinogenesis.

  3. RUNX1T1 serves as a common angiogenic driver for vaculogenesis and functionality of endothelial lineage cells

  4. Leukaemogenesis by AML1-ETO requires enhanced C/D box snoRNA/RNP formation.

  5. Data show that RUNX1-ETO;c-Kit(T417IDelta418-419) coexpression promoted exclusively acute myeloid leukemia (AML) in a fraction (51%) of reconstituted mice.

  6. Self-renewal induced by AML1/ETO in primary murine progenitors was inhibited when Aes was decreased or absent.

  7. AML1-ETO synergizes with an ICSBP deficiency to induce myeloblastic transformation in the bone marrow, reminiscent of acute myelogenous leukemia

  8. molecular role for ETO in normal physiology as an inhibitor of C/EBPbeta and a novel regulator of early adipogenesis

  9. the loss of the molecular events of AML1-ETO C-terminal NCoR/SMRT-interacting domain transforms AML1-ETO into a potent leukemogenic protein

  10. p15(Ink4b) loss must be accompanied by additional oncogenic changes for RUNX1-ETO-associated AML to develop

  11. AML1 DNA-binding domain and the ETO NHR2-dimerization domain, but not the ETO NHR1 domain, are critical for the induction of acute myeloid leukemia by AML1-ETO9a

  12. the eTAFH-E protein interaction appears to contribute relatively little to the activity of AML1-ETO

RUNX1T1 profil antigène

Antigen Summary

This gene encodes a member of the myeloid translocation gene family which interact with DNA-bound transcription factors and recruit a range of corepressors to facilitate transcriptional repression. The t(8\;21)(q22\;q22) translocation is one of the most frequent karyotypic abnormalities in acute myeloid leukemia. The translocation produces a chimeric gene made up of the 5'-region of the runt-related transcription factor 1 gene fused to the 3'-region of this gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Alternative splicing results in multiple transcript variants.

Gene names and symbols associated with RUNX1T1

  • runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (runx1t1) anticorps
  • RUNX1 translocation partner 1 L homeolog (runx1t1.L) anticorps
  • RUNX1 translocation partner 1 (RUNX1T1) anticorps
  • runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (Runx1t1) anticorps
  • RUNX1 translocation partner 1 (Runx1t1) anticorps
  • AML1T1 anticorps
  • Cbfa2t1 anticorps
  • Cbfa2t1h anticorps
  • CDR anticorps
  • ETO anticorps
  • MTG8 anticorps
  • si:ch211-232j17.1 anticorps
  • wu:fi14b07 anticorps
  • zgc:154044 anticorps
  • ZMYND2 anticorps

Protein level used designations for RUNX1T1

protein CBFA2T1 , MTG8 , MTG8/ETOb , expressed during postmitotic spinal neurons, most likely in motorneurons , acute myelogenous leukemia 1 translocation 1, cyclin-D related , core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related , eight twenty one protein , myeloid translocation gene on 8q22 , zinc finger MYND domain-containing protein 2 , CBFA2T1 identified gene homolog , acute myelogenous leukemia 1 translocation 1 protein , core-binding factor, runt domain, alpha subunit 2 , cyclin D-related , translocated to, 1

GENE ID SPECIES
767809 Danio rerio
733153 Xenopus laevis
395503 Gallus gallus
862 Homo sapiens
487044 Canis lupus familiaris
12395 Mus musculus
362489 Rattus norvegicus
100155449 Sus scrofa
Fournisseurs de qualité sélectionnés pour RUNX1T1 (RUNX1T1) Kits ELISA
Avez-vous cherché autre chose?